The investor presentation is a routine corporate update with no new material information. Monitor for future SEC filings containing clinical pipeline updates, financial results, or regulatory catalysts for the pz-cel program.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 11 $5.53entry
- T+1 · 5mo ago 0.00%α −0.54% · $5.53
- T+5 · 5mo ago +2.17%α +1.74% · $5.65
- T+20 · 4mo ago +28.75%α +26.86% · $7.12
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona Therapeutics filed an 8-K furnishing an updated investor presentation (Exhibit 99.1) under Item 7.01 for use in meetings with investors and analysts. No material financial data, guidance updates, or business developments were disclosed, this is a routine disclosure of a corporate presentation used for investor relations.
Key Facts
- Filed an 8-K on June 10, 2026 furnishing an updated investor presentation under Item 7.01.
- The presentation is dated June 10, 2026 and is attached as Exhibit 99.1.
- No financial results, guidance, material agreements, or operational updates were disclosed.
- The filing is a routine Regulation FD disclosure for use in investor meetings.
Financial Impact
No financial impact, no material financial data or guidance was provided.
Risk Factors
- No material information disclosed, the presentation may contain forward-looking statements with standard risk factors.
- Biotech sector risks including clinical trial setbacks, regulatory delays, and capital needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-028106 |
| Document: 0001493152-26-028106-index-headers.html | 0001493152-26-028106 |
| Document: 0001493152-26-028106-index.html | 0001493152-26-028106 |
| Document: 0001493152-26-028106.txt | 0001493152-26-028106 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers